Hereditary neuropathy with predisposition to pressure palsy …

Peripheral Neuropathies

Updated 11.09.2023
Released 07.11.2001
Expires For CME 11.09.2026

Hereditary neuropathy with predisposition to pressure palsy

Authors: Florian P Thomas MD MA PhD MS, Francisco de Assis Aquino Gondim MD MSc PhD

See Contributor Disclosures

Editor: Louis H Weimer MD

Hereditary neuropathy with predisposition to pressure palsy

In This Article

Quick Link

Introduction

Overview

Hereditary neuropathy with predisposition to pressure palsy (HNPP) may be considered the genetic opposite of CMT1A, the single most common subtype of Charcot-Marie-Tooth disease, as it is most often caused by a heterozygous deletion of the same gene region containing the PMP22 gene that is duplicated in CMT1A. HNPP may be the inherited neuropathy with the widest phenotypic range.

Historical note and terminology

Inherited peripheral neuropathies were described independently by Charcot and Marie (30) in France and by Tooth in England (174), but earlier descriptions had been published, including several by Friedreich (53). Complex forms of Charcot-Marie-Tooth disease are recognized occasionally with associated mental retardation, upper motor neuron signs, deafness, optic atrophy, pigmentary retinal degeneration, and various extraneural manifestations. The heterogeneous nature of the disorder was soon recognized. Thus, Dejerine and Sottas described in Charcot's group more severe cases with onset in infancy (39), and Roussy and Levy described cases associated with tremor, which were defined genetically (149; 07; 136). Allan recognized different forms of inheritance (03). With the advent of neurophysiological testing, a stringent classification became possible. Early studies suggested that patients with Charcot-Marie-Tooth disease could be divided into one group with slow nerve conduction velocities and pathological evidence of a hypertrophic demyelinating neuropathy, and a second group with relatively normal velocities and axonal or neuronal degeneration (ie, hereditary motor and sensory neuropathy type 2 or Charcot-Marie-Tooth disease type 2) (47; 173; 25). The features of Charcot-Marie-Tooth disease type 1 and type 2 were outlined in two landmark publications detailing the genetic and clinical characteristics of more than 200 patients (69; 70). Most patients with Charcot-Marie-Tooth disease have an autosomal dominant pattern, whereas other patients inherit the disease through an X-linked recessive or autosomal recessive pattern.

De Jong described hereditary neuropathy with predisposition to pressure palsy (HNPP) in a Dutch coal miner, who had been working in a squatting position, and four relatives from three generations, who grubbed potatoes. De Jong found low vitamin B1 levels in several of these patients and considered this a possible cause of their disorder (40; 85). A case of HNPP from this original family has been described (86). Davies, Wahle, and Tonnis observed pressure-sensitive neuropathies in a father and son with recurrent multiple mononeuropathies (36; 182). Diminished conduction velocity and action potential amplitude along motor and sensory nerves in affected and unaffected nerves with focal conduction slowing or block at common entrapment sites were described in several families with HNPP (48; 161). A 4-generation Dutch family referred to affected members with transient unilateral peroneal neuropathies as having bulb diggers' palsy (161). Behse recognized the sausage-like swellings of the myelin sheaths, which later were considered pathognomonic. Madrid and Bradley contributed the ultrastructural changes in HNPP; they proposed several mechanisms for the development of focal myelin thickening and coined the term tomaculous neuropathy (105). Dayan and colleagues reported similar histologic features, termed “globular neuropathy,” in a family with progressive weakness and numbness of apparent autosomal dominant inheritance (38). Larger literature reviews and personally observed series of patients with clinical electrodiagnostic and histological correlation were reported by Roos and Thygesen (148), Meier and Moll (115), and Pellissier and colleagues (135).

In the 1980s linkages to chromosomes 1, 17, and X were recognized for certain Charcot-Marie-Tooth pedigrees, and Charcot-Marie-Tooth disease was subcategorized to cover hereditary motor and sensory neuropathy type 1A (70% to 80%), type 1B (4% to 5%), and X-linked Charcot-Marie-Tooth disease (141; 179; 119; 92). In 1991, two groups showed that Charcot-Marie-Tooth type 1A, the most common form of the type 1 disease, was associated with a 1.5 mB duplication within chromosome 17p11.2 (51; 103; 142). Ninety percent of these cases result from this duplication (24; 68; 188; 132). Mutations in the peripheral myelin protein 22 kD gene, contained within the 1.5 kB duplication on chromosome 17, have been demonstrated to cause demyelinating neuropathies in Trembler and Trembler-J mice (165; 167) and in some Charcot-Marie-Tooth disease type 1 or type 3 patients (176; 146; 122). Moreover, transgenic mice and rats over-expressing PMP22 develop neuropathies resembling Charcot-Marie-Tooth disease type 1 (75; 106; 156). An approximately 1.5 mB long deletion of the proximal short arm of chromosome 17 is detected in most families with HNPP (27; 74), whereas about 14% to 25% of patients develop the disorder due to other PMP22 mutations (124; 123). The deletion includes all markers duplicated in Charcot-Marie-Tooth disease type 1A. Several nondeletion mutations have been identified: nonsense mutations with a stop codon at G183A (Trp61stop) and at G372A (Trp124stop); frameshift mutations with premature termination at 19delAG to 20delAG and 434delT, or with a longer transcript at 281insG to 282insG; splice site mutations at 78+1G>T, 179+1G>C; missense mutations at G208A (Val30Met) in exon 3 (124; 169; 170; 22; 189; 95; 151); and small deletion of exon 5 leading to very mild phenotype (26). A similar condition, hereditary brachial plexus neuropathy (or hereditary neuralgic amyotrophy with predilection for the brachial plexus), is not linked to the PMP22 locus but was mapped to chromosome 17q25 (28; 65; 187; 134).

The 1990s also saw the identification of other Charcot-Marie-Tooth genes: myelin protein zero for Charcot-Marie-Tooth disease type 1 and type 3 (71; 90; 164) and the gap junction protein connexin 32 or beta 1 on chromosome Xq13.1 (12). The rare X-linked Charcot-Marie-Tooth disease was mapped to chromosome Xq24 to Xq26 (139) and the zinc-finger domain-containing transcription factor early growth response 2 gene for congenital hypomyelination neuropathy and Charcot-Marie-Tooth disease type 1D (185). Mutations of all of these genes have been associated with several overlapping clinical phenotypes. For instance, Dejerine-Sottas syndrome is associated with PMP22 or myelin protein zero mutations or deletions (123; 184; 43; 144).

Several disease linkages and genes have been identified: two signal transduction genes; the N-MYC downstream-regulated gene-1 on chromosome 8q24.3 for the Lom form of autosomal recessive motor and sensory neuropathy (hereditary motor sensory neuropathy or Charcot-Marie-Tooth disease type 4D) (81); the gene for the phosphatase myotubularin-related protein-2 on chromosome 11q22 for autosomal recessive Charcot-Marie-Tooth disease type 4B (20); a cytoskeletal gene; the neurofilament light subtype gene on chromosome 8p21 for Charcot-Marie-Tooth disease type 2E (117); the periaxin gene on chromosome 19q13.1-2, which is regulated by EGR2, for recessive Dejerine-Sottas syndrome (18); the gene for a serine palmitoyltransferase subunit on chromosome 9q22 for hereditary sensory neuropathy type 1 (11; 37); and the KIF1B-beta gene involved in axonal organelle transport on chromosome 1p36-35 for Charcot-Marie-Tooth disease type A (190). Demyelinating neuropathy also results from absent proteolipid protein expression in some patients with Pelizaeus-Merzbacher (61; 60). Mutations in the cytoskeletal protein gigaxonin have been linked to giant axonal neuropathy (21). A locus for autosomal dominant Charcot-Marie-Tooth disease type 2F was found on chromosome 7q11-q21 (77).

Loci with several candidate genes have been identified in two families with autosomal dominant Charcot-Marie-Tooth disease and conduction velocities between 24 m/s and 54 m/s. One is on chromosome 19p12-p13.2 (82), and the other is associated with both large fiber loss and regeneration clusters as well as onion bulbs and uncompacted enlarged myelin lamellae on chromosome 10q24.1-q25.1 (107; 180). A recessively inherited severe form of Charcot-Marie-Tooth disease with intermediate conduction velocities has been linked to chromosome 10q23 (147). Intermediate conduction velocities also occur with myelin protein zero and neurofilament light subtype gene mutations (42; 41).

Overall, more than 100 genes are known for the different forms of Charcot-Marie-Tooth disease.

Clinical manifestations

Presentation and course

Onset of neuropathies associated with PMP22 deletions or mutations typically occurs during the third or fourth decade but ranges from the first to the eighth; palsy may be present at birth (175). Due to its insidious onset, some patients are unaware of their disease or seek medical attention only late in life; others remain asymptomatic. The condition may occasionally be revealed in later life when individuals develop an acquired unrelated neuropathy due to metabolic derangements, autoimmunity, or neurotoxic drugs.

In typical HNPP, motor symptoms predominate over sensory symptoms. Patients often report that after resting on a limb in an awkward position, the resulting weakness and dysesthesias last weeks to months, rather than seconds to minutes. Rarely, the condition may mimic stroke-like episodes (66). Slight compression of peripheral nerves and repeated local exercise leads to episodes of weakness with decreased perception to touch and pain. Most attacks are of sudden onset, painless, and initially followed by recovery. Attacks most often present with a single nerve involvement, with onset on awakening. They are usually triggered by mild compression that resolves in days to months. Patients with frequent episodes may have persistent neurologic abnormalities. Precipitating trauma, such as carrying heavy loads, writing, or playing musical instruments, may be minimal and unavoidable. Although pain was long considered a minor symptom of HNPP, it appears to affect 42.1% of patients (45). In a series of 17 patients with HNPP, most had transient focal weakness or sensory loss related to activities that may compress nerves (97). None had a symmetric CMT1A-like phenotype. The authors postulated that PMP22 may stabilize myelin and protect nerves from repetitive, minor trauma. Del Colle and colleagues (44) reported carpal tunnel syndrome without episodes of nerve palsy as the presentation in a PMP22 deletion family; electrodiagnostic testing revealed a sensorimotor polyneuropathy with delayed sensorimotor latencies.

HNPP is not the only manifestation of PMP22 deletions. In multiple case reports and three large series, several other phenotypes have been identified (129; 175; 130; 91; 120). It is important to keep in mind that atypical presentations occur and that HNPP must be considered in the differential diagnosis of many different forms of neuropathy. In a study, 40% were unaware of their condition, and 25% were essentially without symptoms (129). The most common presentation is recurrent acute mononeuropathy often related to minor nerve compression. Sites of compression are often those of anatomic vulnerability: the fibular neck for the peroneal nerve; the cubital tunnel for the ulnar nerve; the spiral groove of the humerus for the radial nerve; and the carpal tunnel for the median nerve. Many other sites may exist, however, as evidenced by the report of a lesion of the anterior branch of the axillary nerve. This is likely due to compression against the surgical neck of the humerus (159). In a study of 70 patients, the average number of nerve palsies over a lifetime was around two (120); the most commonly affected structure was the peroneal nerve, followed by the ulnar, the brachial plexus, and the radial and median nerves; and weakness persisted for more than 3 months in 15% of patients. Orstavik and colleagues reported a family in which three members had brachial plexus palsies as the only clinical manifestation of HNPP (127). The brachial plexopathy form of HNPP may be recurrent, isolated, or part of other multiple mononeuropathies and is painless, which differentiates it from hereditary neurologic amyotrophy (23; 113; 162). Furthermore, there is no genetic overlap between the two conditions (28; 65; 187; 134). In the study by Mouton and colleagues, 10 patients had sensory deficits in addition to palsies (120). In patients with the recurrent pattern, the exam between episodes may be normal or mildly abnormal. There may be distal and mild pansensory loss. Reflexes are normal in about two thirds of patients. In one study, ankle jerks were absent in 37.5% of patients, and areflexia occurred in 12.5% (65). The second most frequent presentation in two series (129; 91), though rarer in another (120), was a largely symmetric, slowly progressive polyneuropathy, giving rise to a misdiagnosis of Charcot-Marie-Tooth disease. With this subtype, high arches and hammertoes are common. Scoliosis is rarely seen. Some patients have recurrent, sensory symptoms lasting minutes to hours triggered by limb position or nerve compression. Others present with a chronic sensory polyneuropathy. Rarely, patients present with subacute recurrent or confluent demyelinating multiple mononeuropathies and are misdiagnosed as acute or chronic inflammatory demyelinating polyneuropathy (80; 93; 91). Cranial neuropathies, including recurrent Bell palsy (137), deafness (55), laryngeal (126; 33) and swallowing dysfunction (102), bilateral successive hypoglossal nerve injuries following carotid endarterectomies with only partial recovery (34), phrenic nerve involvement (33), and lumbosacral radiculopathies (31) have been reported. Greater occipital neuropathy was observed by Dr. Florian P Thomas in three members of one family (143). Association with autonomic involvement has been observed by Dr. Florian P Thomas and others (150; 186).

Other rare associations of HNPP include CNS demyelination (04), moving toes and myoclonus (158), fulminant 4-limb weakness possibly related to nerve compression (35) and amyotrophic lateral sclerosis (15). Lynch and Hennessy (104) reported sciatic neuropathy as the initial presentation of HNPP. Subclinical CNS involvement consists of abnormal blink and jaw-opening reflexes and acoustic evoked potentials (168). Normal-appearing white matter in HNPP demonstrated lower fractional anisotropy values by diffusion tensor imaging in the frontal, orbitofrontal, and temporal lobes (183). The co-occurrence of schwannomas in the median and medial plantar nerves and HNPP led to speculations about a possible common genetic basis (72). Other atypical phenotypes/disease associations and combinations of genetic mutations may delay the diagnosis, such as HNPP and amyotrophic lateral sclerosis (15) and HNPP and oculopharyngeal muscular dystrophy (112).

Some patients are oligosymptomatic or asymptomatic, but their exam during evaluations may reveal subtle abnormalities such as distal hyporeflexia or Tinel signs. This is illustrated by a study of monozygotic twin sisters and their father (08). Only one twin was clinically affected. Significant conduction slowing in motor and sensory nerves was recorded in the clinically unaffected twin and the father. Not surprisingly, patients may evolve from one phenotype to another, and different phenotypes may coexist in a family. These are the phenotypic presentations associated with PMP22 deletions, but rare instances of mutations other than PMP22 deletion result in additional specific phenotypes. Although several patients with HNPP and frameshift, nonsense, or splice site mutations had typical phenotypes, likely because the mutations resulted in a functional deletion (124; 169; 129; 170), several families with the disorder due to base insertions leading to an altered longer protein that could disturb Schwann cell function and normal myelin formation have additional features reminiscent of Charcot-Marie-Tooth disease type 1 (95). A mild phenotype resulted from a 3' splice-site mutation, preceding coding exon 3 (c.179-1 G> C) (118). Atypical phenotypes may also result from a combination of mutations. In one family, Pegoraro reported co-segregation of Lamin A/C and PMP22 mutations, leading to a more severe phenotype with unusual axonal involvement in addition to a typical myelinopathy (133).

HNPP rarely presents in childhood. A 2-year-old child presented with toe-walking, pain, stiffness, asymmetric weakness, and bilateral upper motor neuron findings (99). Five years later, the patient developed episodic numbness and weakness in the arms and borderline conduction velocities, and HNPP was diagnosed.

Undiagnosed HNPP in an oligosymptomatic patient may complicate the treatment and diagnosis of an acquired neuromuscular disease later in life. For instance, a person with the disorder may, in his sixties, become diabetic and develop diabetic amyotrophy. A patient with HNPP may also acquire chronic inflammatory demyelinating polyneuropathy. Such a patient's clinical and electrical presentation may be unusual and difficult to understand unless a diagnosis of HNPP is also considered. Even more importantly, such a patient's spontaneous recovery or positive treatment response may be disappointing and far less complete than expected, had the acquired neuropathy been the only condition.

Given the short recovery time and oligosymptomatic or asymptomatic nature of diseases associated with PMP22 deletions in many patients, the course is often mild, and disability is subtle. However, patients with progressive polyneuropathy with recurrent episodes of palsy in one nerve may be left with significant disability. Foot deformities may be significant. Because the family history may be truly or falsely negative, a clinical history of transient or recurrent neurologic symptoms with clinical and electrodiagnostic abnormalities in affected and unaffected sites can guide further genetic testing (14).

Prognosis and complications

Life expectancy is usually normal. There is no primary treatment for HNPP. In general, patients with hereditary liability to pressure palsies have an excellent quality of life. About 10% of patients make an incomplete recovery from episodes of nerve palsy. Koike and colleagues reported progressive age-related irreversible motor axonal damage at entrapment sites, whereas sensory involvement did not change with age (87). Although direct and indirect health care calculations cannot typically be easily transposed from one country to another, the first study to ever assess the average cost of Charcot-Marie-Tooth disease provided an estimate of $22,362 per patient in Germany, with the cost of HNPP much lower at $7928. Cost predictors included disease severity, age, Charcot-Marie-Tooth disease subtype, comorbidities, body mass index, and employment status (155). Quality of life was impaired in HNPP to the same degree as in CMT1A (16). Fatigue can lead to decreased quality of life, even with mild neurologic impairment (54).

Clinical vignette

A 42-year-old man (IV-3) was referred for evaluation of diffuse body aches. He gave a history of episodic bilateral wrist drop, intermittent limb numbness (after repetitive movements in particular), and frequent muscle cramps since the age of 20. His examination showed fairly subtle abnormalities. Sensation was diminished to all modalities in a right ulnar and peroneal as well as left median and ulnar distribution. Power, bulk, gait, and coordination were intact, but there was distal hyporeflexia in the arms and legs. Tinel signs were present at the wrists and elbows. No nerves could be palpated. Hammertoes and high arches were present. Routine labs, erythrocyte sedimentation rate, B12, folate, rapid plasma reagin, antinuclear antibodies, rheumatoid factor, thyroid function, HgA1c, creatine kinase, and HIV antibodies were noncontributory, but hepatitis C serology was positive. His 65-year-old mother gave a history of finger numbness and post-partum arm weakness and had distal hyporeflexia and decreased sensation. His 81-year-old great-aunt was similarly affected. His daughter, 18 years of age, had numbness and tingling in the back of her legs during gym class and middle finger numbness when holding a pen but denied episodic weakness; symptom onset was at the age of 13. She had high arches and hammertoes, slightly weak finger extension, mild distal pansensory impairment, and a Romberg sign. Her 15-year-old sister was reluctant to attend gym class because of foot numbness; symptoms improved when she shook her legs. Either hand occasionally went numb, especially the right thumb when writing. Once after sitting on her cousin's shoulders, both legs were weak for some 20 minutes. Her examination was remarkable only for weak interossei in both hands. Two younger children were asymptomatic but had distal pinprick and vibratory sense loss with normal proprioception, strength, and reflexes.

Tomaculous neuropathy classical findings

(A) Semithin cross-section shows a marked depletion of myelinated nerve fibers. Several myelinated fibers have a thick myelin sheath and an irregular contour, suggesting that they are tomacula. (B) Teased fibers reveal globular ex...

Electrodiagnostic studies in 1987, 1988, and 1996 in the father revealed multiple nerve entrapments at both median and ulnar nerves at the wrists, the ulnar nerves at the elbows, the right radial nerve at the spiral groove, and the right peroneal nerve at the fibular head. Conduction velocities were normal or low normal except for slowing in the demyelinative range at areas of nerve entrapment, where amplitudes were also low. There was no significant change over time in nerves studied repeatedly.

Light and electron microscopy of the father's sural nerve biopsy showed a prominent sausage-shaped expansion of the myelin sheath in the perinodal and internodal regions, the classical finding that gives this condition its other name, tomaculous neuropathy, thinly myelinated fibers, and reduction in large myelinated fiber density with a shift of fiber diameters to small sizes. There were areas of incomplete myelin compaction and of redundant loops of the myelin sheath.

Tomaculous neuropathy classical findings

(A) Semithin cross-section shows a marked depletion of myelinated nerve fibers. Several myelinated fibers have a thick myelin sheath and an irregular contour, suggesting that they are tomacula. (B) Teased fibers reveal globular ex...
Myelinated fibers in tomaculous neuropathy

Decreased myelinated fiber density. Histometric measurements showed a unimodal distribution of myelinated fibers with a shift of the peak to diameters between 3 µm and 7 µm. (Contributed by Dr. Florian Thomas.)

Genetic testing revealed a deletion of the 1.5 MB gene region that harbors the PMP22 gene in all affected family members and in the two asymptomatic younger daughters.

This family illustrates the typical presentation of PMP22 deletions, but the diagnosis is not always as straightforward. They had the classic history of recurrent pressure-related mononeuropathies at common entrapment points as well as typical clinical, electrodiagnostic, histological, and genetic findings. Symptoms were often induced by relatively minor trauma. Onset was in the second or third decade. Most episodes were of rapid onset, painless, and usually followed by complete recovery. They noticed that the nerve palsies, instead of clearing in seconds to minutes, persisted for days or weeks. Adults and children in this family realize this susceptibility and avoid situations from which pressure palsies may result. Only the father sought medical attention on his own. Not only the symptomatic relatives, but even the asymptomatic younger children had evidence of more generalized neuropathic disease with hyporeflexia, distal sensory loss, or subtle weakness, and several had skeletal deformities.

Biological basis

Etiology and pathogenesis

PMP22 mutation diseases are typically inherited in an autosomal dominant fashion, but de novo mutations have been documented for HNPP (145). Sixty-eight percent to 90% of these cases (111; 94; 123) are caused by a 1.5 mB deletion that includes the PMP22 gene within chromosome 17p11.2, the same region that is duplicated in Charcot-Marie-Tooth disease type 1A, although some do result from smaller deletions (29) or mutations within the PMP22 gene (124). The fact that both PMP22 deletions and frameshift or nonsense mutations are associated with HNPP suggests a loss of function mechanism. This notion is supported by the finding of PMP22 underexpression in patient and transgenic mouse nerve tissue and of a similar clinical and histological phenotype in humans and animal models. Deletions of paternal origin make up 87% and are caused by unequal meiotic cross-over between both chromosome 17 homologs, whereas the much rarer maternal deletions result from an intrachromosomal process (128; 101; 100; 17). The 1.5 mB gene region is flanked by homologous replication gene sequences, which serve as substrates for the recombination step required for deletion. These replication gene sequences contain regions homologous to so-called mariner insect transposons. Although these regions do not encode a transposase, this enzyme function provided from elsewhere in the genome could act on the mariner insect transposons and, thus, could explain the unexpectedly high frequency of recombination at this hotspot and of the PMP22 gene region duplication. Other genes reside in the 1.5 mB region, and their monosomy in HNPP could conceivably contribute to the phenotype.

PMP22 is a 160 amino acid peptide with an apparent molecular weight of 18 kD (22 kD after glycosylation) that is highly conserved in evolution. It is most highly expressed in Schwann cells, where it localizes to compact myelin, but is also expressed in the brainstem and spinal motor neurons. Its four membrane-spanning domains may indicate a pore function; however, the presence of the L2/HNK-1 carbohydrate epitope suggests a role in cell adhesion, as is the case for myelin protein zero, myelin-associated glycoprotein, and neural cell adhesion molecule (79). PMP22 expression is tightly regulated at the transcriptional level by the use of two different promoters, of which P1 contains several regulatory elements and appears to function in myelinating Schwann cells (67). It is conceivable that mutations in such elements could be responsible for some cases of inherited neuropathies; however, this is not yet commercially testable. PMP22 expression is also controlled at the translational level, possibly through axonal signaling, with decreased expression in the distal nerve stump following injury and the reverse during regeneration. It also plays a role in the cell cycle (as indicated by its other name, growth arrest-specific gene). In vitro, PMP22 overexpression not only delays Schwann cell progression through the cell cycle into division, but also causes programmed cell death or apoptosis. Underexpression accelerates cell proliferation (121).

Likely mutations of individual myelin genes do not act in isolation to cause the different forms of Charcot-Marie-Tooth disease; they interact with each other. Colocalization and complex formation of myelin protein zero and PMP22 in compact myelin, as well as the presence of the L2/HNK-1 carbohydrate epitope on both, may indicate that these two molecules interact in a heterophilic interaction (46), an attractive hypothesis given their similar expression and gene regulation and the clinical and histological analogies between Charcot-Marie-Tooth disease type 1A and type B and HNPP. This interaction could be disrupted by PMP22 or myelin protein zero overexpression, underexpression, or point mutations. However, myelin gene mutations have further far-reaching consequences. For instance, it was shown that Trembler mouse Schwann cells are deficient in glial cell-derived neurotrophic factor, nerve growth factor, and brain-derived neurotrophic factor, which could lead to impaired axonal and myelin maintenance (52).

The focus of active research is the process by which PMP22 deletions, duplications, and other mutations cause HNPP, Charcot-Marie-Tooth disease type 1A, and other conditions. The gene deletion is responsible for diminished PMP22 mRNA and protein (178; 58; 154), but PMP22 nonsense and point mutations result in an early stop codon and a truncated protein and, thus, also cause neuropathy by protein underexpression. Several transgenic mouse studies have addressed the role of PMP22 underexpression. Animals under-expressing PMP22 as a result of a heterozygous knock-out or an antisense PMP22 transgene resemble HNPP (02; 01; 114). Heterozygous knock-out mice display mild neurophysiological changes and focal, often perinodal, hypermyelination when younger. However, these changes appear to be unstable and evolve into a predominantly demyelinating appearance in older animals. This overlap obviously appears analogous to the manifestations in humans that can range from typical HNPP to typical Charcot-Marie-Tooth disease. The seeming instability of tomacula may also be an explanation of the transient nature of symptoms in HNPP, although the same histologic hallmarks are also characteristic of some myelin protein zero mutations in a nonrecurrent hereditary neuropathy, Charcot-Marie-Tooth disease type 1B (172). Homozygous PMP22-deficient animals have delayed myelination and weakness at 2 weeks, frequent tomacula at 3 weeks, severe nerve conduction slowing, onion bulbs and other signs of demyelination or remyelination when older than 2 months, and axonal atrophy at 1 year of age (166). A naturally occurring disease of cattle is characterized by abnormal gait, gastrointestinal features, and tomaculous neuropathy (73).

Although myelin abnormalities are the pathological hallmark of PMP22 deletions, axonal loss likely contributes to the clinical manifestations that are especially late during the disease course. The process by which Schwann cell mutations induce axonal degeneration is one of the most exciting areas of investigation.

Nerve ultrasound suggests that the disproportional distal slowing in HNPP may result from a combination of mechanical insults and an axon-initiated process in the distal nerves leading to conduction failure. Increased distal motor latencies occurred independently of nerve enlargement seen by ultrasound (62).

Epidemiology

Charcot-Marie-Tooth disorders are among the most common inherited neurologic disorders, but estimates of their frequency vary. An exhaustive study from Norway indicated a prevalence of 36 per 100,000 (160), whereas a worldwide meta-analysis estimated a prevalence of 10 in 100,000 (49). On the other hand, the frequency of HNPP is not well documented. A single study of 435,000 individuals in Finland reported a prevalence of 16/100,000 for the disorder and of 20/100,000 for Charcot-Marie-Tooth disease in general (116). Although this is less than the previously reported frequency of Charcot-Marie-Tooth disease of 36/100,000 in Norway, it is an indication that HNPP is not a rare condition. As both diseases result from unequal crossover during meiosis, similar epidemiological data are to be expected. Likely diseases associated with PMP22 gene deletions or protein truncations are underdiagnosed due to the variable phenotype, the insidious nature of the disease, and the many mildly affected patients. HNPP may be more common, with an earlier age of onset in men, possibly due to environmental (nerve trauma) or X-linked genetic factors (120). Epidemiologic features were similar in a Korean series compared to Western countries; disease onset appeared to be earlier in patients with recurrent nerve palsies versus those with single attacks (83). Among 11,885 Korean newborns tested by next-generation sequencing-based copy number variation analysis, 17p11.2 deletions were found in 7, for an estimated prevalence of 58.9 per 100,000 (131). Of some 1000 individuals with Charcot-Marie-Tooth disease at a single center in the United States, 6% had HNPP (153). Men are more severely affected clinically (higher number of nerve palsies) and electrodiagnostically (110).

Differential diagnosis

Recurrent pressure palsy originating at typical entrapment sites and involving one or more nerves warrants the diagnostic consideration of HNPP. Hereditary neurologic amyotrophy is another autosomal dominant condition with recurrent mononeuropathies. It shares a predominance of tomaculous changes with HNPP, although axonal changes distal to the plexus suggest a strong axonal component. Hereditary neurologic amyotrophy is distinguished by several factors, including prominent, often severe, movement-dependent pain that typically precedes other symptoms; abnormalities that typically affect the brachial plexus in an isolated fashion; occasional dysmorphic features of the face and short stature; and the absence of an associated polyneuropathy. This condition is genetically distinct from HNPP and maps to chromosome 17q25 (28; 65; 187; 134). Familial carpal tunnel syndrome, though rare and often difficult to ascertain, appears to be another entity that must be considered (63). Patients with other phenotypes of PMP22 deletions are more difficult to diagnose. In these, the first challenge may be to demonstrate that a patient's weakness and sensory loss do indeed result from peripheral nerve disease and not from abnormalities elsewhere. Proof can usually be accomplished by a clinical examination revealing focal or distal weakness, muscle wasting, sensory loss, and hyporeflexia. If the patient has a neuropathy and a positive family history, a Charcot-Marie-Tooth disorder becomes likely. Pedigree analysis can clarify inheritance patterns. However, the absence of a family history does not eliminate consideration of a hereditary PMP22 mutation, because relatives may be oligosymptomatic or asymptomatic, or disease may result from a de novo mutation. In one report, 37% of patients had no family history (175). Infante and colleagues suggested that in the absence of familial history, HNPP should be strongly considered in patients with nerve palsies or atypical clinical presentations as well as generalized abnormalities of nerve conduction preferentially at common entrapment sites and distal nerve segments (76).

Other conditions that may directly or indirectly lead to recurrent or isolated painless mononeuropathies or plexopathy must be excluded. These conditions include alcohol abuse, trauma, diabetes mellitus, porphyria, hypothyroidism, uremia, vasculitis, and ischemia. Furthermore, HNPP can mimic chronic inflammatory demyelinating polyneuropathy (108; 50; 109; 93; 88), which could also be superimposed on oligosymptomatic or asymptomatic HNPP. Although highly unlikely to be misdiagnosed as Guillain-Barré syndrome, challenging and atypical cases can be considered psychiatric disease, and misdiagnosis of HNPP as Guillain-Barré syndrome has been reported (191).

Diagnostic workup

The purpose of studies in patients with a possible inherited neuropathy is to confirm or refute this working diagnosis and to ascertain the presence of a treatable condition (eg, nerve entrapment that might be amenable to surgery or a superimposed acquired neuropathy). This workup should include tests that address causes of neuropathies such as endocrinological, infectious, and immunological abnormalities, vitamin and nutritional deficiencies, and nerve compression.

Cerebrospinal fluid analysis is usually normal, but protein levels may be elevated, as documented in an HNPP case manifesting as recurrent polyradiculoneuropathy (93).

MRI of the leg and foot muscles may be useful in the evaluation of disease progression. Gallardo found that early involvement was restricted to intrinsic foot muscles in a cohort of 11 patients with CMT1A. Patients with more advanced disease also had variable involvement of proximal leg muscles. Findings included atrophy, fatty infiltration, edema, and contrast enhancement. Abnormalities were also found in clinically normal muscles (59). MRI parameters may be useful biomarkers to evaluate disease progression in HNPP (138).

Genetic testing. Patients in whom the clinical phenotype, family history, and electrodiagnostic studies suggest that they might have an inherited neuropathy should be genotyped. This is important because clinical examination and electrodiagnostic studies often cannot definitively establish a precise diagnosis due to the overlap between clinical syndromes and the significant variability between family members with an identical genotype. Genotyping permits sound genetic and prognostic counseling and advances the scientific understanding of phenotypes. In a study, de novo mutations accounted for 21% of HNPP families (76). Although oral mucosal swabs or saliva or blood samples are usually required for DNA analysis, a report documented that chromosomal changes of the PMP22 gene can be diagnosed in up to 12-year-old highly degraded DNA from sural nerve biopsies (09).

Electrodiagnostic studies. These can separate HNPP from other inherited or acquired neuropathies. Typically there is background polyneuropathy independent of superimposed entrapment neuropathy. The variability within families may be considerable. Stringent criteria have been proposed to facilitate the distinction between HNPP and other causes. In a series of 99 patients with a PMP22 deletion, Mouton and colleagues found a multifocal polyneuropathy with diffusely increased distal motor latencies, more normal motor conduction velocities, diffuse reduction if sensory nerve action potentials, and multiple instances of focal slowing at anatomical entrapment sites (120). These features, including focal slowing, were also observed in several patients with a Charcot-Marie-Tooth phenotype without recurrent nerve palsies. This indicates that neurophysiologic testing can lead to an HNPP diagnosis, even when the clinical features do not suggest it. Neurophysiologic findings were similar in oligosymptomatic and asymptomatic patients and became characteristic as early as the second decade. EMG is normal in proximal muscles but may show distal changes with increased duration and amplitude motor unit potentials. Signs of active denervation such as increased insertional activity and fibrillation potentials are not prominent in muscles unaffected by weakness. Diagnostic criteria for the disorder have been proposed based on bilaterally delayed median distal motor latencies, slowed median sensory conduction at the wrist, and prolonged distal motor latencies or motor conduction slowing in the peroneal nerves (64). Other criteria were proposed by Infante and colleagues (76). Bilaterally normal median distal motor latencies and sensory velocities at the wrist appear to exclude HNPP.

Andersson and colleagues found diffuse sensory conduction slowing independent of nerve entrapment in the vast majority of their own nine and 53 previously reported cases, consistent with a background of demyelinative distal polyneuropathy (05). Slowed motor conduction was less common in HNPP, although distal motor latencies were frequently prolonged in the study’s own and previously published patients, indicating that there is a distal motor polyneuropathy, similar to that seen in IgM monoclonal gammopathy against myelin-associated glycoprotein or sulfated glucuronyl paragloboside. The authors suggested that a profile of conduction velocity slowing in most sensory nerves, relatively less frequent and more minor motor slowing, and prolonged distal motor and F-wave latencies were characteristic of HNPP. However, Li and colleagues disagreed with the concept of distal myelinopathy and suggested that focal susceptibility to compression was the main culprit (98). In their study, distal slowing correlated with exposure to entrapment; there was more slowing in the median and peroneal and less in the ulnar and peroneal.

Neuropathologic studies. Both motor and sensory fibers in most nerves show segmental demyelination and remyelination; variable, secondary, and axonal loss; and focal thickening of the myelin sheath or tomacula (10; 105; 57; 152). Outside of the tomacula the ratio of axon and fiber diameter (g ratio) is normal. Onion bulb formation and increase in endoneurial connective tissue are limited. Tomacula are more often perinodal than internodal. Nodes of Ranvier are often obscured, probably by transnodal myelin. There may be branching and duplication of the mesaxons, and more than one Schwann cell may participate in myelination (105). Ultrastructurally, tomacula appear as redundant myelin loops, both external and internal, with intramyelinic folds. Uncompacted myelin is typically rare but was prominent in diffuse and focal forms in the sural nerve of a 16-year-old girl with HNPP due to a PMP22 gene deletion (78).

A teased fiber analysis of 37 biopsies found features of demyelination and remyelination as well as tomacula in all cases. About 23% of fibers were normal, 52% showed evidence of demyelination or remyelination; 54% of the fibers had tomacula with a mean diameter and length of 16.3 µm and 83.7 µm, respectively (152). Focal myelin thickening, although a hallmark of HNPP, is not restricted to this condition. It occurs to various degrees with Charcot-Marie-Tooth disease type 1B, immune-mediated neuropathies, hereditary neuropathies with myelin outfolding, and others. It can occur experimentally from pressure injury (125; 181; 177; 56; 172; 140; 152).

An issue with important implications for molecular pathogenesis is the reason for tomacula formation. Ochoa and colleagues explained pressure-induced myelin abnormalities with slippage of myelin lamellae (125). Gabreels-Festen and van de Wetering proposed that, in HNPP, the genetic defect disturbs adhesion of myelin lamellae and makes them susceptible to displacement (57). The susceptibility of nerve biopsies from patients and PMP22 deletion transgenic mice to artifacts supports the exquisite sensitivity to mechanical forces. Gabreels-Festen and van de Wetering suggested that tomacula are accumulated due to everyday injuries that patients may not notice, whereas more intense or longer injuries displace sufficient myelin lamellae to cause demyelination and conduction block with palsies.

Interestingly, several conditions in which tomacula occur result from either antibodies binding to proteins in compact myelin carrying the L2/HNK-1 epitope or from genetic defects in the proteins themselves. This is the case for myelin protein zero, PMP22, and myelin-associated glycoprotein (myelin protein zero may be a binding partner for L2/HNK-1). Mutations in these genes and myelin-associated glycoprotein antibodies are also associated with widening of the myelin lamellae. Although altered PMP22 function may play a role in some mutations, PMP22 deletion results in underexpression of PMP22 mRNA that correlates with disease severity, axon diameter, and g ratio, but not with myelin thickness, number of tomacula, or nerve conduction parameters (154). Mutations of the connexin32 gene that are not expressed in compact myelin and do not carry the L2/HNK-1 epitope are not associated with tomacula formation in Charcot-Marie-Tooth disorder type X. Sander and colleagues, Gabreels-Festen, and van de Wetering proposed that myelin proteins expressing or reacting with HNK-1 are crucial in myelin adhesion and tomacula formation (57; 152). However, it remains unexplained why tomacula, indistinguishable histologically, are associated with liability to pressure palsies in some conditions but not others. It is likely that additional genes expressed in peripheral nerves are also involved, as the gene in two other conditions with focal myelin thickening, hereditary neurologic amyotrophy, and hereditary motor and sensory neuropathy with myelin outfolding have not been identified, although gene linkages have been established to chromosomes 17q25 and 11q23, respectively (19; 134). Further insight may result from studies of human nerve xenografts into nude mice (151).

There is some evidence that immune dysregulation may play a role in the pathogenesis of hereditary neuropathies, including HNPP (88). Sural nerve biopsies in the disorder and other Charcot-Marie-Tooth cases show major histocompatibility complex (MHC) class II upregulation, but not inflammatory infiltrates (163).

Li and colleagues advocate skin biopsies as a less invasive alternative in the evaluation of myelin-related neuropathies and have shown myelin abnormalities in all patients with CMT diseases. PMP22 mRNA and protein levels were increased in CMT1A and decreased in HNPP (96).

Management

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

It is important to prevent, look for, and treat acquired neuropathies as well as to avoid compression neuropathies. This may require adjustments in lifestyle and avoidance of job-related nerve injury.

Patients, family members, and physicians need to be aware of drugs and vitamin supplements that can affect the peripheral nervous system. Drugs and vitamins with various degrees of neurotoxicity include the following:

Adriamycin
Alcohol
Amiodarone
Chloramphenicol
Cisplatin
Colchicine
Dapsone
Disulfiram
Ethionamide
Glutethimide
Gold
Hydralazine
Isoniazid
Lithium
Metronidazole
Misonidazole
Nitrofurantoin
Nitrous oxide
Paclitaxel
Penicillamine
Penicillin (high doses)
Perhexiline
Phenytoin
Vincristine
Vitamin A
Vitamin B6 (high doses)
Vitamin D

Nutritional and vitamin deficiencies. Patients should maintain a well-balanced diet and avoid obesity, which can contribute to spinal root disease and certain entrapment neuropathies (meralgia paresthetica).

Physical therapy and prosthetics. Physical therapy may be useful during episodes of nerve palsy to maintain range of motion and prevent joint deformities and contractures. Physical therapy can be beneficial for the long term in PMP22 deletion or mutation patients with prominent features of an inherited polyneuropathy. Prosthetic devices such as ankle-foot orthoses can prevent Achilles tendon shortening and extend near normal ambulation. At times, boots can delay the need for such ankle braces. In case of arm and hand weakness, thick-handle tools and cutlery can render certain activities of daily living easier. Shoe inserts to relieve pressure of pressure points, together with scheduled foot inspections, may prevent the development of foot ulcers in patients who progress to a chronic polyneuropathy.

Pain. Although HNPP is typically pain-free, pain may result from joint deformities or compensatory overuse of certain muscle groups during episodes of nerve palsy. Some types of pain may respond to nonsteroidal anti-inflammatory drugs. Dysesthetic pain may occur; it responds to antidepressants such as amitriptyline, desipramine, or paroxetine as well as to anticonvulsants such as gabapentin or carbamazepine.

Surgery. In rare cases of foot deformities, patients with HNPP or other PMP22 deletion mutations may benefit from Achilles tendon lengthening, tendon transfers, hammer toe correction, and release of the plantar fascia. The response to nerve entrapment surgery is often suboptimal, and surgeons must be aware of the diagnosis because, as discussed above, the nerves are exquisitely sensitive to trauma. Treatment of carpal tunnel syndrome but not of ulnar entrapment has been recommended for HNPP (32).

Treatment. The introduction of recombinant DNA encoding normal PMP22 into the nerves of knock-out mice is being considered a therapeutic strategy. Another approach explores neurotrophin gene transfer into the spine. The identification of regulatory PMP22 promoter sequences might open venues for therapeutic intervention if drugs could be designed to allow modulation of gene expression (67). The significance of steroid-responsive palsies (08) is difficult to appreciate in light of the natural history of HNPP, which is remitting. In a rat model of CMT1A, a selective progesterone antagonist improved the CMT phenotype, whereas administration of progesterone increased PMP22 and MPZ mRNA expression and Schwann cell pathology and led to clinical progression (157). Of course, sex hormones cannot easily be used in humans in this fashion, but drugs could be engineered to increase PMP22 expression selectively in nerve for use by patients with HNPP.

Media

References

01: Adlkofer K, Frei R, Neuberg DH, Zielasek J, Toyka KV, Suter U. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci 1997;17:4662-71. PMID 9169527
02: Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 1995;11:274-80. PMID 7581450
03: Allan W. Relation of hereditary pattern to clinical severity as illustrated by peroneal atrophy. Arch Intern Med 1939;63:1123-31.
04: Amato A, Barohn R. Hereditary neuropathy with liability to pressure palsies: association with central nervous system demyelination. Muscle Nerve 1996;19:770-3. PMID 8609929
05: Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 2000;54:40-4. PMID 10636123
06: Antognini J. Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases. Can J Anaesth 1992;39:398-400. PMID 1563065
07: Auer-Grumbach M, Strasser-Fuchs S, Wagner K, Korner E, Fazekas F. Roussy-Levy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2. J Neurol Sci 1998;154:72-5. PMID 9543325
08: Barisic N, Skarpa D, Jusic A, Jadro-Santel D. Steroid responsive familial neuropathy with liability to pressure palsies. Neuropediatrics 1990;21:191-2. PMID 2290479
09: Beckmann A, Schroeder JM. Screening for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsy in archival nerve biopsy samples by direct-double-differential PCR. Acta Neuropathol 2000;100:459-63. PMID 11045666
10: Behse F, Buchthal F, Carlsen F, Knappeis GG. Hereditary neuropathy with liability to pressure palsies: eletrophysiological and histopathological aspects. Brain 1972;95:777-94. PMID 4345910
11: Bejaoui K, Wu C, Sheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001;27(3):261-2. PMID 11242106
12: Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262:2039-42. PMID 8266101
13: Bernard R, Labelle V, Negre P, et al. Prenatal detection of a 17p11.2 duplication resulting from a rare recombination event and novel PCR-based strategy for molecular identification of Charcot-Marie-Tooth disease type 1A. Eur J Hum Genet 2000;8(3):229-35. PMID 10780790
14: Beydoun SR, Sykes SN, Ganguly G, Lee TS. Hereditary neuropathy with liability to pressure palsies: description of seven patients without known family history. Acta Neurol Scand 2008;117(4):266-72. PMID 17922888
15: Bhatt A, Farooq MU, Aburashed R, et al. Hereditary neuropathy with liability to pressure palsies and amyotrophic lateral sclerosis. Neurol Sci 2009;30(3):241-5. PMID 19238316
16: Bjelica B, Peric S, Bozovic I, et al. Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A. Acta Neurol Belg 2020. [Epub ahead of print] PMID 32335868
17: Boerkoel CF, Inoue K, Reiter LT, Warner LE, Lupski JR. Molecular mechanisms for CMT1A duplication and HNPP deletion. Ann N Y Acad Sci 1999;883:22-35. PMID 10586226
18: Boerkoel C, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001;68(2):325-33. PMID 11133365
19: Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet 1996;5(7):1051-4. PMID 8817346
20: Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000;25(1):17-9. PMID 10802647
21: Bomont P, Cavalier L, Blondeau F, et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 2000;26(3):370-4. PMID 11062483
22: Bort S, Nelis E, Timmerman V, et al. Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. Hum Genet 1997;99(6):746-54. PMID 9187667
23: Bosch E, Chui H, Martin M, Cancilla PA. Brachial plexus involvement in familial pressure-sensitive neuropathy: eletrophysiological and morphological findings. Ann Neurol 1980;8(6):620-4. PMID 7212650
24: Brice A, Ravise N, Stevanin G, et al. Duplication within chromosome 17p11.2 in 12 patients of French ancestry with Charcot-Marie-Tooth disease type 1a. The French CMT Research Group. J Med Genet 1992;29(11):807-12. PMID 1453432
25: Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings. Brain 1977;100:41-66. PMID 861715
26: Casasnovas C, Banchs I, De Jorge L, et al. A novel small deletion in PMP22 causes a mild hereditary neuropathy with liability to pressure palsies phenotype. Muscle Nerve 2012;45(1):135-8. PMID 22190321
27: Chance PF, Alderson MK, Leppig KA, et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993;72(1):143-51. PMID 8422677
28: Chance PF, Lensch MW, Lipe H, et al. Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies: two distinct genetic disorders. Neurology 1994;44(12):2253-7. PMID 7991108
29: Chapon F, Diraison P, Timmerman V, et al. Hereditary neuropathy with liability to pressure palsies with a partial deletion of the region often duplicated in Charcot-Marie-Tooth disease, type 1A. J Neurol Neurosurg Psychiatry 1996;61(5):535-6. PMID 8937360
30: Charcot JM. Sur une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jambes et atteingnant plus tard les mains. Rev Med 1886;6:97-138.
31: Choi YH, Dunn B. Low back pain with radicular symptoms as a presentation of hereditary neuropathy with liability to pressure palsies: the diagnostic challenge of an atypical presentation. Muscle Nerve 2016;53(4):655-6. PMID 26773980
32: Chompoopong P, Niu Z, Shouman K, et al. Utility of carpal tunnel release and ulnar decompression in CMT1A and HNPP. Muscle Nerve 2022;66(4):479-86. PMID 35894586
33: Cortese A, Piccolo G, Lozza A, et al. Laryngeal and phrenic nerve involvement in a patient with hereditary neuropathy with liability to pressure palsies (HNPP). Neuromuscul Disord 2016;26(7):455-8. PMID 27241821
34: Corwin HM, Girardet RE. Hereditary neuropathy with liability pressure palsies mimicking hypoglossal nerve injuries. Neurology 2003;61(10):1457-8. PMID 14638986
35: Crum B, Sorenson E, Abad G, Dyck PJ. Fulminant case of hereditary neuropathy with liability to pressure palsy. Muscle Nerve 2000;23(6):979-83. PMID 10842280
36: Davies DM. Recurrent peripheral-nerve palsies in a family. Lancet 1954;2:266. PMID 13184660
37: Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001;27:309-12. PMID 11242114
38: Dayan AD, Graveson GS, Robinson PK, Woodhouse MA. Globular neuropathy. A disorder of axons and Schwann cells. J Neurol Neurosurg Psychiatry 1968;31(6):552-60. PMID 4303801
39: Dejerine H, Sottas J. Sur la nevrite interstitielle, hypertrophique et progressive de l’enfance. CR Soc Biol (Paris) 1893;45:63-96.
40: De Jong JG. Over families met hereditaire dispositie tot het optreden van neuritiden, gecorreleerd met migraine. Psychiat Neurol Bl Amst 1947;50:60-76.
41: De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene muations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001;49(2):245-9. PMID 11220745
42: De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999;122(Pt 2):281-90. PMID 10071056
43: De Jonghe P, Timmerman V, Nelis E, De Jonghe P, Timmerman V, Nelis E. Charcot- Marie-Tooth Disease and related peripheral neuropathies. J Periph Nerv Syst 1997;2(4):370-87. PMID 10975746
44: Del Colle R, Fabrizi GM, Turazzini M, Cavallaro T, Silvestri M, Rizzuto N. Hereditary neuropathy with liability to pressure palsies: electrophysiological and genetic study of a family with carpal tunnel syndrome as only clinical manifestation. Neurol Sci 2003;24(2):57-60. PMID 12827539
45: Dukefoss TT, Kleggetveit IP, Helås T, Jørum E. Pain and small-fiber affection in hereditary neuropathy with liability to pressure palsies (HNPP). Scand J Pain 2019;20:61-8. PMID 31536037
46: D'Urso D, Erhardt P, Muller H. Peripheral myelin protein 22 and protein zero: a novel association in peripheral nervous system myelin. J Neurosci 1999;19:3396-403. PMID 10212299
47: Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-18. PMID 4297451
48: Earl CJ, Fullerton PM, Wakefield GS, Schutta HS: Hereditary neuropathy, with liability to pressure palsies. A clinical and electrophysiological study of four families. Q J Med 1964;33:481-98. PMID 14212604
49: Emery AE. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991;1:19-29. PMID 1822774
50: Felice KJ, Poole RM, Blaivas M, Albers JW. Hereditary neuropathy with liability to pressure palsies masquerading as slowly progressive polyneuropathy. Eur Neurol 1994;34:173-6. PMID 8033945
51: Fischbeck KH, ar-Rushdi N, Pericak-Vance M, Rozear M, Roses AD, Fryns JP. X-linked neuropathy: gene localization with DNA probes. Ann Neurol 1986;20:527-32. PMID 3024556
52: Friedman HC, Aguayo AJ, Bray GM. Trophic factors in neuron-Schwann cell interactions. Ann N Y Acad Sci 1999;883:427-38. PMID 10586266
53: Friedreich N. Uber progressive Muskelatrophie, uber wahre und falsche Muskelhypertrophie. Berlin: Hirschwald, 1873.
54: Fritz NE, Chen Y, Waters L, et al. Fatigue in patients with hereditary neuropathy with liability to pressure palsies. Ann Clin Transl Neuro 2020;7(8):1400-9. PMID 32856791
55: Gabreels-Festen A, Gabreels FJ, Joosten EM, Vingerhoets HM, Renier WO. Hereditary neuropathy with liability to pressure palsies in childhood. Neuropediatrics 1992;23:138-43. PMID 1322507
56: Gabreels-Festen A, Joosten EM, et al. Congenital demyelinating motor and sensory neuropathy with focally folded myelin sheath. Brain 1990;113(Pt 6):1629-43. PMID 2276038
57: Gabreels-Festen A, van de Wetering R. Human nerve pathology caused by different mutational mechanisms of the PMP22 gene. Ann N Y Acad Sci 1999;883:336-43. PMID 10586258
58: Gabriel J, Erne B, Pareyson D, Sghirlanzoni A, Taroni F, Steck AJ. Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies. Neurology 1997;49(6):1635-40. PMID 9409359
59: Gallardo E, Garcia A, Combarros O, Berciano J. Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 2006;129:426-37. PMID 16317020
60: Garbern JY, Cambi F, Lewis R, et al. Peripheral neuropathy caused by proteolipid protein gene mutations. Ann NY Acad Sci 1999;883:351-65. PMID 10586260
61: Garbern JY, Cambi F, Tang XM, et al. Proteolipid protein is necessary in peripheral as well as central myelin. Neuron 1997;19(1):205-18. PMID 9247276
62: Ginanneschi F, Filippou G, Giannini F, et al. Sonographic and electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. J Peripher Nerv Syst 2012;17(4):391-8. PMID 23279340
63: Gossett JG, Chance PF. Is there a familial carpal tunnel syndrome. An evaluation and literature review. Muscle Nerve 1998;21:1533-6. PMID 9771681
64: Gouider RL, Gugenheim M, Tardieu S, et al. Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion. Neurology 1995;45(11):2018-23. PMID 7501152
65: Gouider R, LeGuern E, Emile J, et al. Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies: two distinct clinical, eletrophysiologic, and genetic entities. Neurology 1994;44:2250-2. PMID 7991107
66: Hachisuka A, Matsushima Y, Hachisuka K, Saeki S. A case of apoplexy attack-like neuropathy due to hereditary neuropathy with liability to pressure palsies in a patient diagnosed with chronic cerebral infarction. J Stroke Cerebrovasc Dis 2016;25(6):e83-5. PMID 27080157
67: Hai M, Bidichandani SI, Patel PI. Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. J Neurosci Res 2001;65:508-19. PMID 11550219
68: Hallam PJ, Harding AE, Berciano J, Barker DF, Malcolm S. Duplication of part of chromosome 17 is commonly associated with hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease type 1). Ann Neurol 1992;31:570-2. PMID 1596093
69: Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathies types I and II. Brain 1980a;103:259-80. PMID 7397478
70: Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980b;17:329-36. PMID 7218272
71: Hayasaka K, Ohnishi A, Takada G, Fukushima Y, Murai Y. Mutation of the myelin P0 gene in Charcot-Marie-Tooth neuropathy type-1. Biochem Biophys Res Commun 1993;194(3):1317-22. PMID 7688964
72: Heckmann JG, Dutsch M, Buslei R. Hereditary neuropathy with liability to pressure palsy combined with schwannomas of the median and medial plantar nerves. Muscle Nerve 2007;35(1):122-4. PMID 16969831
73: Hill B, Prior H, Blakemore W, Black PF. A study of pathology of a bovine primary peripheral neuropathy with features of tomaculous neuropathy. Acta Neuropathol 1996;91(5):545-8. PMID 8740237
74: Hoogendijk JE, De Visser M, Bolhuis PA, Hart AA, Ongerboer de Visser BW. Hereditary motor and sensory neuropathy type I: clinical and neurographical features of the 17P duplication subtype. Muscle Nerve 1994;17:85-90. PMID 8264707
75: Huxley C, Passage E, Manson A, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996;5(5):563-9. PMID 8733121
76: Infante J, Garcia A, Combarros O, et al. Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletion. Muscle Nerve 2001;24(9):1149-55. PMID 11494267
77: Ismailov SM, Fedotov VP, Dadali EL, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001;9(8):646-50. PMID 11528513
78: Jedrzejowska H, Fidzianska A, Kochanski A. Uncompacted myelin in hereditary neuropathy with liability to pressure palsies with the 17 p11.2 deletion. Folia Neuropathol 1999;37:220-6. PMID 10705641
79: Jetten AM, Suter U. The peripheral myelin protein and epithelial membrane protein family. Prog Nuclei Acid Res Mol Biol 2000;64:97-129. PMID 10697408
80: Joy J, Oh S. Tomaculous neuropathy presenting as acute recurrent polyneuropathy. Ann Neurol 1989;26:98-100. PMID 2549849
81: Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 2000;67(1):47-58. PMID 10831399
82: Kennerson ML, Zhu D, Gardner RJ, et al. Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2. Am J Hum Genet 2001;69(4):883-8. PMID 11533912
83: Kim SM, Chung KW, Choi ES, et al. Hereditary neuropathy with liability to pressure palsies (HNPP) patients of Korean ancestry with chromosome 17p11.2-p12 deletion. Exp Mol Med 2004;36:28-35. PMID 15031668
84: Kinsella LJ, Green R. 'Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. Neurology 1995;45:1608-10. PMID 7644061
85: Koehler PJ. Hereditary neuropathy with liability to pressure palsies: the first publication (1947). Neurology 2003;60(7):1211-3. PMID 12682341
86: Koehler PJ, Baas F. Hereditary neuropathy with liability to pressure palsies. Diagnosis in the first family (1947) confirmed. J Peripher Nerv Syst 2012;17(4):412-3. PMID 23279343
87: Koike H, Hirayama M, Yamamoto M, et al. Age associated axonal features in HNPP with 17p11.2 deletion in Japan. J Neurol Neurosurg Psychiatry 2005;76:1109-14. PMID 16024889
88: Korn-Lubetzki I, Argov Z, Raas-Rothschild A, Wirguin I, Steiner I. Family with inflammatory demyelinating polyneuropathy and HNPP 17p12 deletion. Am J Med Genet 2002;113(3):275-8. PMID 12439896
89: Kramer M, Ly A, Li J. Phenotype HNPP (hereditary neuropathy with liability to pressure palsies) induced by medical procedures. Am J Orthop (Belle Mead NJ) 2016;45(1):E27-8. PMID 26761923
90: Kulkens T, Bolhuis PA, Wolterman RA, et al. Deletion of the serine 34 codon from the major peripheral myelin protein gene in Charcot-Marie-Tooth disease type 1B. Nat Genet 1993;5(1):35-9. PMID 7693130
91: Kumar N, Cole J, Parry G. Variability of presentation in hereditary neuropathy with liability to pressure palsy results in underrecognition. Ann N Y Acad Sci 1999;883:344-50. PMID 10586259
92: Lebo RV, Chance PF, Dyck PJ, et al. Chromosome 1 Charcot-Marie-Tooth disease (CMT1B) locus in the Fc gamma receptor gene region. Hum Genet 1991;88(1):1-12. PMID 1683643
93: Le Forestier N, LeGuern E, Coullin P, et al. Recurrent polyradiculoneuropathy with the 17p11.2 deletion. Muscle Nerve 1997;20(9):1184-6. PMID 9270678
94: LeGuern E, Gouider R, Lopes J, et al. Constant rearrangement of the CMT1A-REP sequences in HNPP patients with a deletion in chromosome 17p11.2: a study of 30 unrelated cases. Hum Mol Genet 1995;4(9):1673-4. PMID 8541860
95: Lenssen P, Gabreels-Festen A, Valentijn L, et al. Hereditary neuropathies with liability to pressure palsies. Phenotypic differences between patients with the common deletion and a PMP22 frame shift mutation. Brain 1998;121(Pt 8):1451-8. PMID 9712007
96: Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 2005;128:1168-77. PMID 15774502
97: Li J, Krajewski K, Lewis RA, Shy ME. Loss-of-function phenotype of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2004;29(2):205-10. PMID 14755484
98: Li J, Krajewski K, Shy ME, Lewis RA. Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology 2002;58(12):1769-73. PMID 12084875
99: Lonnqvist T, Pihko H. Hereditary neuropathy with liability to pressure palsies (HNPP) in a toddler presenting with toe-walking, pain and stiffness. Neuromuscular Dis 2003;13:827-9. PMID 14678806
100: Lopes J, Ravise N, Vandenberghe A, et al. Fine mapping of de novo CMT1A and HNPP rearrangements within CMT1A-REPs evidences two distinct sex-dependent mechanisms and candidate sequences involved in recombination. Hum Mol Genet 1998;7(1):141-8. PMID 9384615
101: Lopes J, Vandenberghe A, Tardieu S, et al. Sex-dependent rearrangements resulting in CMT1A and HNPP. Nat Genet 1997;17(2):136-7. PMID 9326925
102: Lorenzoni PJ, Scola RH, Cardoso J, et al. Swallowing dysfunction in hereditary neuropathy with liability to pressure palsies. Arq Neuropsiquiatr 2008;66(4):898-900. PMID 19099137
103: Lupski JR, de Oca-Luna RM, Slaugenhaupt S. DNA duplication associated with Charcot-Marie-Tooth Disease Type 1A. Cell 1991;66:219-32. PMID 1677316
104: Lynch JM, Hennessy M. HNPP presenting as sciatic neuropathy. J Peripher Nerv Syst 2005;10:1-2. PMID 15703012
105: Madrid R, Bradley WG. The pathology of neuropathies with focal thickening of the myelin sheath (tomaculous neuropathy). J Neurol Sci 1975;25:415-48.
106: Magyar JP, Martini R, Ruelicke T, et al. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996;16(17):5351-60. PMID 8757248
107: Malandrini A, Ceuterick C, Villanov M, et al. Ultrastructural findings in the peripheral nerve in a family with the intermediate form of Charcot-Marie-Tooth disease. J Submicrosc Cytol Pathol 2001;33(1-2):59-63. PMID 11686409
108: Malandrini A, Guazzi G, Frederico A. Sensorimotor chronic neuropathy in two siblings: atypical presentation of tomaculous neuropathy. Clin Neuropathol 1992:11:318-22. PMID 1473315
109: Mancardi G, Mandich P, Nassani S, et al. Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. J Neurol Sci 1995;131(1):30-4. PMID 7561944
110: Manganelli F, Pisciotta C, Dubbioso R, et al. Electrophysiological comparison between males and females in HNPP. Neurol Sci 2013;34(8):1429-32. PMID 23207550
111: Mariman EC, Gabreels-Festen AA, van Beersum SE, et al. Evidence for genetic heterogeneity underlying hereditary neuropathy with liability to pressure palsies. Hum Genet 1994;93(2):151-6. PMID 8112739
112: Marsh EA, Robinson DO. A case of rare recessive oculopharyngeal muscular dystrophy (OPMD) coexisting with hereditary neuropathy with liability to pressure palsies (HNPP). Clin Neurol Neurosurg 2008;110(5):525-8. PMID 18358598
113: Martinelli P, Fabbri R, Moretto G, Gabellini AS, D'Alessandro R, Rizzuto N. Recurrent familial brachial plexus palsies as the only clinical expression of 'tomaculous' neuropathy. Eur Neurol 1989;29:61-6. PMID 2540008
114: Maycox PR, Ortuno D, Burrola P, et al. A transgenic mouse model for human hereditary neuropathy with liability for human hereditary neuropathy with liability to pressure palsies. Mol Cell Neurosci 1997;8(6):405-16. PMID 9143558
115: Meier C, Moll C. Hereditary neuropathy with liability to pressure palsies. J Neurol 1982;228:73-95. PMID 6185651
116: Meretoja P, Silander K, Kalimo H, Aula P, Meretoja A, Savontaus ML. Epidemiology of hereditary neuropathy with liability to pressure palsies (HNPP) in south western Finland. Neuromus Disord 1997;7(8):529-32. PMID 9447611
117: Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000;67(1):37-46. PMID 10841809
118: Meuleman J, Pou-Serradell A, Lofgren A, et al. A novel 3'-splice site mutation in peripheral myelin protein 22 causing hereditary neuropathy with liability to pressure palsies. Neuromuscul Disord 2001;11(4):400-3. PMID 11369192
119: Middleton-Price HR, Harding AE, Monteiro C, Berciano J, Malcolm S. Linkage of hereditary motor and sensory neuropathy type Ito the pericentromeric region of chromosome 17. Am J Hum Genet 1990;46:92-4. PMID 2294757
120: Mouton P, Tardieu S, Gouider R, et al. Spectrum of clinical and eletrophysiologic features in HNPP patients with the 17p11.2 deletion. Neurology 1999;52(7):1440-6. PMID 10227632
121: Muller HW. New vistas on the pathomechanism of Charcot-Marie-Tooth and related peripheral neuropathies. Ann N Y Acad Sci 1999;883:152-9. PMID 10586241
122: Nelis E, Timmerman V, De Jonghe P, et al. Rapid screening of myelin genes in CMT1 patients by SSCP analysis: identification of new mutations and polymorphisms in the P0 gene. Hum Genet 1994;94(6):653-7. PMID 7527371
123: Nelis E, Van Broeckhoven C, De Jonghe P. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Gen 1996;4:25-33. PMID 8800924
124: Nicholson G, Valentijn L, Cherryson A, et al. A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies. Nat Genet 1994;6(3):263-6. PMID 8012388
125: Ochoa J, Danta G, Fowler T, Gilliatt RW. Nature of the nerve lesion caused by a pneumatic tourniquet. Nature 1971;233(5317):265-6. PMID 4999642
126: Ohkoshi N, Kohno Y, Hayashi A, Wada T, Shoji S. Acute vocal cord paralysis in hereditary neuropathy with liability to pressure palsies. Neurology 2001;56(10):1415. PMID 11376203
127: Orstavik K, Skard Heier M, Young P, Stögbauer F. Brachial plexus involvement as the only expression of hereditary neuropathy with liability to pressure palsies. Muscle Nerve 2001;24:1093-6. PMID 11439387
128: Palau F, Lofgren A, De Jonghe P, et al. Origin of the de novo duplication in Charcot-Marie-Tooth disease type 1A: unequal nonsister chromatid exchange during spermatogenesis. Hum Mol Genet 1993;2(12):2031-5. PMID 8111370
129: Pareyson D, Scaioli V, Taroni F, et al. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology 1996;46(4):1133-7. PMID 8780105
130: Pareyson D, Solari A, Taroni F, et al. Detection of hereditary neuropathy with liability to pressure palsies among patients with acute painless mononeuropathy or plexopathy. Muscle Nerve 1998;21(12):1686-91. PMID 9843070
131: Park JE, Noh SJ, Oh M, Cho DY, Kim SY, Ki CS. Frequency of hereditary neuropathy with liability to pressure palsies (HNPP) due to 17p11.2 deletion in a Korean newborn population. Orphanet J Rare Dis 2018;13(1):40. PMID 29544507
132: Patel PI, Lupski JR. Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease. Trends Genet 1994;10:128-33. PMID 7518101
133: Pegoraro E, Gavassini BF, Benedetti S, et al. Co-segregation of LMNA and PMP22 gene mutations in the same family. Neuromuscul Disord 2005;15:858-62. PMID 16288874
134: Pellegrino JE, Rebbeck TR, Brown MJ, Bird TD, Chance PF. Mapping of hereditary neuralgic amyotrophy (familial brachial plexus neuropathy) to distal chromosome 17q. Neurology 1997;46:1128-32. PMID 8780104
135: Pellissier J, Pouget J, Victor B. Neuropathie Tomaculaire. Etude histopathologique et correlations eletrocliniques dans 10 cas. Rev Neurol 1987;143:263-78. PMID 3476973
136: Plante-Bordeneuve V, Guiochon-Mantel A, Lacroix C, Lapresle J, Said G. The Roussy-Levy family: from the original description to the gene. Ann Neurol 1999;46:770-3. PMID 10553995
137: Poloni TE, Merlo IM, Alfonsi E, et al. Facial nerve is liable to pressure palsy. Neurology 1998;51(1):320-2. PMID 9674839
138: Pridmore M, Castoro R, McCollum MS, Kang H, Li J, Dortch R. Length‐dependent MRI of hereditary neuropathy with liability to pressure palsies. Ann Clin Transl Neurol 2020;7(1):15-25. PMID 31872979
139: Priest JM, Fischbeck KH, Nouri N, Keats BJ. A locus for axonal motor-sensory neuropathy with deafness and mental retardation maps to Xq24-q26. Genomics 1995;29:409-2. PMID 8666389
140: Quattrone A, Gambardella A, Bono F, et al. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths : clinical, electrophysiologic, and genetic aspects of a large family. Neurology 1996;46(5):1318-24. PMID 8628474
141: Raeymaekers P, De Jonghe P, Backhovens H, et al. Absence of genetic linkage of Charcot-Marie-Tooth disease (HMSN Ia) with chromosome 1 gene markers. Neurology 1989;39(6):844-6. PMID 2725880
142: Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991;1(2):93-7. PMID 1822787
143: Rao CV, Diamond AL, Thomas FP. Greater occipital nerve involvement in hereditary neuropathy with liability to pressure palsy (HNPP). Ann Neurol 2004;56:S61.
144: Reilly ME, Mantle D, Richardson PJ. Studies on the time-course of ethanol's acute effects on skeletal muscle protein synthesis: comparison with acute changes in proteolytic activity. Alcohol Clin Exp Res 1997;21(5):792-8. PMID 9267527
145: Reisecker F, Leblhuber F, Lexner R, Radner G, Rosenkranz W, Wagner K. A sporadic form of hereditary neuropathy with liability to pressure palsies: clinical, electrodiagnostic, and molecular genetic findings. Neurology 1994;44:753-5. PMID 7909361
146: Roa BB, Garcia CA, Suter U, et al. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med 1993;329(2):96-101. PMID 8510709
147: Rogers T, Chandler D, Angelicheva D, et al. A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23. Am J Hum Genet 2000;67(3):664-71. PMID 10915613
148: Ross D, Thygesen P. Familial recurrent polyneuropathy. A family and a survey. Brain 1972;95:235-48. PMID 4347629
149: Roussy G, Levy G. A sept cas d'une maladie familiale particulaire. Rev Neurol 1926;33:427-50.
150: Ruhoy I, Oakley J, Jayadev S, Weiss M. Two siblings with genetically proven HNPP and autonomic neuropathy. Neurology 2015;84(Supplement):P2.037.
151: Sahenk Z, Chen L, Freimer M. A novel PMP22 point mutation causing HNPP phenotype. Neurology 1998;51:702-7. PMID 9748013
152: Sander S, Ouvrier RA, McLeod JG, Nicholson GA, Pollard JD. Clinical syndromes associated with tomacula or myelin swellings in sural nerve biopsies. J Neurol Neurosurg Psychiatry 2000;68:483-8. PMID 10727485
153: Saporta AS, Sottile SL, Miller LJ, Feely SME, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69(1):22-33. PMID 21280073
154: Schenone A, Nobbio L, Caponnetto C, et al. Correlation between PMP-22 messenger RNA expression and phenotype in hereditary neuropathy with liability to pressure palsies. Ann Neurol 1997;42(6):866-72. PMID 9403478
155: Schorling E, Thiele S, Gumbert L, et al. Cost of illness in Charcot-Marie-Tooth neuropathy:results from Germany. Neurology 2019;92(17):e2027-37. PMID 30918088
156: Sereda M, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996;16(5):1049-60. PMID 8630243
157: Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9(12):1533-7. PMID 14608378
158: Shaibani A, Gooch C, Harati Y. Moving toes and myoclonus associated with hereditary neuropathy with liability to pressure palsy (HNPP). Muscle Nerve 1997;20:881-3. PMID 9179161
159: Simonetti S. Lesion of the anterior branch of axillary nerve in a patient with hereditary neuropathy with liability to pressure palsies. Eur J Neurol 2000;7:577-9. PMID 11054147
160: Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118. PMID 4430158
161: Staal A, De Weerdt CJ, Went LN. Hereditary compression syndrome of peripheral nerves. Neurology 1965;15:1008-17. PMID 4285163
162: Stogbauer F, Young P, Kerschensteiner M, Ringelstein EB, Assmann G, Funke H. Recurrent brachial plexus palsies as the only clinical expression of hereditary neuropathy with liability to pressure palsies associated with a de novo deletion of the peripheral myelin protein-22 gene. Muscle Nerve 1998;21(9):1199-201. PMID 9703447
163: Stoll G, Gabreels-Festen A, Jander S, et al. Major Histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type I and hereditary neuropathy with liability to pressure palsies. Muscle Nerve 1998;21:1419-27. PMID 9771665
164: Su Y, Brooks DG, Li L, et al. Myelin protein zero gene mutated in Charcot-Marie-Tooth disease type 1B patients. Proc Natl Acad Sci U S A 1993;90:10856-60. PMID 7504284
165: Suter U, Moskow JJ, Welcher AA, et al. A leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci USA 1992a;89(10):4382-6. PMID 1374899
166: Suter U, Nave K. Transgenic mouse models of CMT1A and HNPP. Ann NY Acad Sci 1999;883:247-53. PMID 10586249
167: Suter U, Welcher AA, Ozcelik T, et al. Trembler mouse carries a point mutation in a myelin gene. Nature 1992b;356(6366):241-4. PMID 1552943
168: Tackenberg B, Moller JC, Rindock H, et al. CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology 2006;67(12):2250-2. PMID 17190957
169: Taroni F, Botti S, Sghirlanzoni A, et al. A nonsense mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies (HNPP) not associated with the 17p11.2 deletion. Am J Hum Genet 1995;57:229.
170: Taroni F, Botti S, Sghirlanzoni A, Pareyson D. PMP22 and MPZ point mutations in Italian families with hereditary neuropathy with liability to pressure palsies (HNPP) and Dejerine-Sottas disease (DSD). Am J Hum Genet 1996;59:A288.
171: Thomas FP, Geller TJ, Hahn AF, et al. Modification of CMT1A phenotypes by independent coexisting neurogenetic disorders, McArdle disease and chromosome 5p trisomy. Ann N Y Acad Sci 1999;883:472-6. PMID 10586277
172: Thomas FP, Lebo RV, Rosoklija G, et al. Tomaculous neuropathy in chromosome 1 Charcot-Marie-Tooth syndrome. Acta Neuropathol 1994;87(1):91-7. PMID 7511317
173: Thomas PK, Calne DB. Motor nerve conduction in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry 1974;37:68-75. PMID 4813428
174: Tooth HH. The peroneal type of progressive muscular atrophy. London: Lewis, 1886.
175: Tyson J, Malcom S, Thomas PK, Harding AE. Deletions of chromosome 17p11.2 in multifocal neuropathies. Ann Neurol 1996;39:180-6. PMID 8967749
176: Valentijn LJ, Baas F, Wolterman RA, et al. Identical point mutations of peripheral myelin protein 22 kD in Trembler-J mouse and Charcot-Marie-Tooth disease Type-1A. Nat Genet 1992;2(4):288-91. PMID 1303281
177: Vallat JM, Gil R, Leboutet MJ, Hugon J, Moulies D. Congenital hypo- and hypermyelination neuropathy. Acta Neuropathol 1987;74(2):197-201. PMID 3673511
178: Vallat JM, Sindou P, Preux PM, et al. Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Ann Neurol 1996;39(6):813-7. PMID 8651657
179: Vance JM, Nicholson GA, Yamaoka LH, et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol 1989;104(2):186-9. PMID 2707366
180: Verhoeven K, Villanova M, Rossi A, Malandrini A, De Jonghe P, Timmerman V. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001;69:889-94. PMID 11533914
181: Vital C, Pautrizel B, Lagueny A, et al. Hypermyelinisation dans un cas de neuropathie peripherique avec gammopathie monoclonale benigne a IgM. Rev Neurol 1985;141(11):729-34. PMID 3003872
182: Wahle VH, Tonnis D. Familiare Anfalligkeit gegenuber Druckschadigungen peripherer Nerven. Fortschr Neurol Psychiatr 1958;26:371-6.
183: Wang WW, Song CL, Huang L, et al. DTI study of cerebral normal-appearing white matter in hereditary neuropathy with liability to pressure palsies (HNPP). Medicine (Baltimore) 2015;94(43):e1909. PMID 26512614
184: Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17(3):451-60. PMID 8816708
185: Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18(4):382-4. PMID 9537424
186: Werheid F, Azzedine H, Zwerenz E, et al. Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene? Brain Behav 2016;6(4):e00451. PMID 27088055
187: Windebank A, Schenone A, Dewald G. Hereditary neuropathy with liability to pressure palsies and inherited brachial plexus neuropathy- two genetically distinct disorders. Mayo Clin Proc 1995;70:743-6. PMID 7630211
188: Wise CA, Garcia CA, Davis SN, et al. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet 1993;53(4):853-63. PMID 8105684
189: Young P, Wiebusch H, Stogbauer F, Young P, Wiebusch H, Stogbauer F. A novel frameshift mutation in PMP22 accounts for hereditary neuropathy with liability to pressure palsies. Neurology 1997;48(2):450-2. PMID 9040737
190: Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor Kif1Bbeta. Cell 2001;105(5):587-97. PMID 11389829
191: Zhu J, Tong X, Li Y, Li G, Pi Z. Hereditary neuropathy with liability to pressure palsies misdiagnosed as Guillain-Barré syndrome: a case report. Medicine (Baltimore) 2022;101:e30768. PMID 36197172

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Florian P Thomas MD MA PhD MS

Dr. Thomas of Hackensack Meridian School of Medicine had no relevant financial relationships to disclose.
See Profile
Francisco de Assis Aquino Gondim MD MSc PhD

Dr. Gondim of Universidade Federal Ceará, Fortaleza, Brazil, received consulting and speaker fees from Pfizer and PTC Therapeutics and travel grants from Daiichi Sankyo Brasil.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Gisele R Oliveira MD

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal dominant

autosomal recessive

sex-linked dominant
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Charcot-Marie-Tooth: 356.1

Hereditary neuropathy with liability to pressure palsies: 356.0
ICD-10: Charcot-Marie-Tooth: G60.0

Hereditary neuropathy with liability to pressure palsies: G60.0
OMIM: Hereditary neuropathy with liability to pressure palsies: #162500

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Hereditary neuropathy with predisposition to pressure palsy

Associated Disorders

Carpal tunnel syndrome
Charcot-Marie-Tooth disease
Hereditary motor and sensory neuropathy

Differential Diagnosis

recurrent pressure palsy
hereditary neurologic amyotrophy
familial carpal tunnel syndrome
Charcot-Marie-Tooth disorder
nerve palsies
- alcohol abuse
- trauma
- diabetes mellitus
- porphyria
- hypothyroidism
- uremia
- vasculitis
- ischemia
- chronic inflammatory demyelinating polyneuropathy

Also Relevant

Brachial neuritis
Carpal tunnel syndrome
Charcot-Marie-Tooth disease type 1A
Charcot-Marie-Tooth disease type 1B
Charcot-Marie-Tooth disease type X
- Charcot-Marie-Tooth disease: CMT2, CMT4, and others
- Molecular diagnosis of neurogenetic disorders
- Rehabilitation of peripheral nerve diseases

Clinical Categories

Peripheral Neuropathies

Hereditary neuropathy with predisposition to pressure palsy …

Hereditary neuropathy with predisposition to pressure palsy

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

Leukodystrophies

Neuroacanthocytosis

Peripheral nerve injuries

Hereditary neuropathy with predisposition to pressure palsy

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

Leukodystrophies

Neuroacanthocytosis

Peripheral nerve injuries

This is an article preview.
Start a Free Account
to access the full version.